These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 9802743)
1. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Tütüncü NB; Bayraktar M; Varli K Diabetes Care; 1998 Nov; 21(11):1915-8. PubMed ID: 9802743 [TBL] [Abstract][Full Text] [Related]
2. Tocotrienol-Rich Vitamin E (Tocovid) Improved Nerve Conduction Velocity in Type 2 Diabetes Mellitus Patients in a Phase II Double-Blind, Randomized Controlled Clinical Trial. Chuar PF; Ng YT; Phang SCW; Koay YY; Ho JI; Ho LS; Botross Henien NP; Ahmad B; Abdul Kadir K Nutrients; 2021 Oct; 13(11):. PubMed ID: 34836025 [TBL] [Abstract][Full Text] [Related]
3. The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial. Ng YT; Phang SCW; Tan GCJ; Ng EY; Botross Henien NP; M Palanisamy UD; Ahmad B; Abdul Kadir K Nutrients; 2020 May; 12(5):. PubMed ID: 32456230 [TBL] [Abstract][Full Text] [Related]
4. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Reljanovic M; Reichel G; Rett K; Lobisch M; Schuette K; Möller W; Tritschler HJ; Mehnert H Free Radic Res; 1999 Sep; 31(3):171-9. PubMed ID: 10499773 [TBL] [Abstract][Full Text] [Related]
5. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Bril V; Buchanan RA Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898 [TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Hotta N; Toyota T; Matsuoka K; Shigeta Y; Kikkawa R; Kaneko T; Takahashi A; Sugimura K; Koike Y; Ishii J; Sakamoto N; Diabetes Care; 2001 Oct; 24(10):1776-82. PubMed ID: 11574441 [TBL] [Abstract][Full Text] [Related]
7. High rat food vitamin E content improves nerve function in streptozotocin-diabetic rats. van Dam PS; Bravenboer B; van Asbeck BS; Marx JJ; Gispen WH Eur J Pharmacol; 1999 Jul; 376(3):217-22. PubMed ID: 10448879 [TBL] [Abstract][Full Text] [Related]
8. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan. Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T; J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462 [TBL] [Abstract][Full Text] [Related]
9. Effect of glycemic control on electrophysiologic changes of diabetic neuropathy in type 2 diabetic patients. Huang CC; Chen TW; Weng MC; Lee CL; Tseng HC; Huang MH Kaohsiung J Med Sci; 2005 Jan; 21(1):15-21. PubMed ID: 15754584 [TBL] [Abstract][Full Text] [Related]
10. Cross sectional study to evaluate the effect of duration of type 2 diabetes mellitus on the nerve conduction velocity in diabetic peripheral neuropathy. Hussain G; Rizvi SA; Singhal S; Zubair M; Ahmad J Diabetes Metab Syndr; 2014; 8(1):48-52. PubMed ID: 24661759 [TBL] [Abstract][Full Text] [Related]
11. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group. Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611 [TBL] [Abstract][Full Text] [Related]
12. The electrophysiological findings of subclinical neuropathy in patients with recently diagnosed type 1 diabetes mellitus. Karsidag S; Morali S; Sargin M; Salman S; Karsidag K; Us O Diabetes Res Clin Pract; 2005 Mar; 67(3):211-9. PubMed ID: 15713353 [TBL] [Abstract][Full Text] [Related]
13. Glycemic control is related to the electrophysiologic severity of diabetic peripheral sensorimotor polyneuropathy. Tkac I; Bril V Diabetes Care; 1998 Oct; 21(10):1749-52. PubMed ID: 9773742 [TBL] [Abstract][Full Text] [Related]
14. [Total antioxidant blood capacity in patients with type 2 diabetes mellitus and distal symmetrical polyneuropathy]. Dordević G; Durić S; Apostolskit S; Dordević V; Zivković M Vojnosanit Pregl; 2008 Sep; 65(9):663-9. PubMed ID: 18814501 [TBL] [Abstract][Full Text] [Related]
15. Effect of folic acid supplementation on nerve conduction velocity in diabetic polyneuropathy patients. Mottaghi T; Khorvash F; Maracy M; Bellissimo N; Askari G Neurol Res; 2019 Apr; 41(4):364-368. PubMed ID: 30730785 [TBL] [Abstract][Full Text] [Related]
16. Effects of glycemic control and aldose reductase inhibition on nerve conduction velocity. Pfeifer MA Am J Med; 1985 Nov; 79(5A):18-23. PubMed ID: 3934964 [TBL] [Abstract][Full Text] [Related]
17. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Jamal GA; Carmichael H Diabet Med; 1990 May; 7(4):319-23. PubMed ID: 2159860 [TBL] [Abstract][Full Text] [Related]
18. Serum levels of TNF-α in peripheral neuropathy patients and its correlation with nerve conduction velocity in type 2 diabetes mellitus. Hussain G; Rizvi SA; Singhal S; Zubair M; Ahmad J Diabetes Metab Syndr; 2013; 7(4):238-42. PubMed ID: 24290092 [TBL] [Abstract][Full Text] [Related]
20. Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes. Astley S; Langrish-Smith A; Southon S; Sampson M Diabetes Care; 1999 Oct; 22(10):1626-31. PubMed ID: 10526726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]